Net Loss (USD, thousands)

Depreciation and Amortization (USD, thousands)

Stock-Based Compensation Expense (USD, thousands)

Change in Fair Value of Warrant Liabilities (USD, thousands)

Accretion and Interest on Short-Term Investments (USD, thousands)

Amortization of Right-of-Use Lease Assets (USD, thousands)

Non-Cash Interest (USD, thousands)

Change in Other Receivables (USD, thousands)

Change in Prepaid Expenses and Other Current Assets (USD, thousands)

Change in Other Assets (USD, thousands)

Change in Accounts Payable and Accrued Expenses (USD, thousands)

Change in Lease Liabilities (USD, thousands)

Change in Other Current Liabilities (USD, thousands)

Net Cash Used in Operating Activities (USD, thousands)

Capital Expenditures (USD, thousands)

Purchases of Short-Term Investments (USD, thousands)

Proceeds from Maturities of Short-Term Investments (USD, thousands)

Net Cash Provided by (Used in) Investing Activities (USD, thousands)

Proceeds from ATM Sales of Common Stock, Net of Issuance Costs (USD, thousands)

Proceeds from Net Settlement of Restricted Share Awards (USD, thousands)

Payment of Debt Issuance Cost (USD, thousands)

Net Cash Provided by Financing Activities (USD, thousands)

Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Additions (Deletions) to Right-of-Use Lease Assets in Exchange for New or Modifications to Operating Lease Liabilities (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at Beginning of Year (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at End of Year (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Restricted Cash (USD, thousands)

Total Cash, Cash Equivalents and Restricted Cash (USD, thousands)

947a42303601fe80c1cb1013570036d0fb7586dadef92752dc1f8099f8811809

License and other revenues (USD, thousands)

Research and development (USD, thousands)

General and administrative (USD, thousands)

Total expenses (USD, thousands)

Loss from operations (USD, thousands)

Interest income (USD, thousands)

Interest expense (USD, thousands)

Change in fair value of warrant and derivative liabilities (USD, thousands)

Other income (USD, thousands)

Net loss (USD, thousands)

74245ca801a232e55a469b9d101aa24694f0c7869c25ed8e40db06931a4454c1

Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Restricted cash (USD, thousands)

Other receivables (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses (USD, thousands)

Current portion of long-term debt (USD, thousands)

Current portion of operating lease liability (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term operating lease liabilities (USD, thousands)

Long-term debt (USD, thousands)

Warrant liabilities (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive loss (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

f8af4d0b84af6f585bcc8c3e058dec554de07a345dbde100311e2ea3dc3623d9

License and other revenues

- Clinical milestone revenue

- Deferred revenue recognition

- Sublease revenue

Total Revenue

3a63e4dadbea4585bdb77905791f9e969f55f7916075136cf8d99d583297b326

Abeona Therapeutics Inc (ABEO)

Financials